Edwards Lifesciences Corporation (NYSE:EW) saw a downside of -0.22% to close Monday at $108.49 after subtracting -$0.24 on the day. The 5-day average trading volume is 2,223,400 shares of the company’s common stock. It has gained $112.52 in the past week. An average of 2,421,235 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,069,934.
EW’s 1-month performance is -10.26% or -$12.40 on its low of $105.66 reached on 10/04/21. The company’s shares have touched a 52-week low of $70.92 and high of $123.27, with the stock’s rally to the 52-week high happening on 09/08/21. YTD, EW has achieved 18.92% or $17.26. However, the current price is down -11.99%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Oct 08, 4 days have gone by since the last insider trading activity for Edwards Lifesciences Corporation (EW). BOBO DONALD E JR (CVP,Strategy/Corp Development) most recently sold 11,050 shares at $110.49 per share on Oct 08. This transaction cost the insider $1,220,881. CVP, Japan & Intercontinental, WANG HUIMIN, sold 6,350 shares at a price of $110.91 on Oct 08. Then, on Oct 01, Chairman & CEO MUSSALLEM MICHAEL A sold 32,550 shares at a price of $111.72 per share. This transaction amounted to $3,636,375.
The company’s PE ratio for the last five years has touched a high of 77.60 and a low of 29.47. EW stock has a beta of 1.01. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 14.00 while the price-to-book (PB) in the most recent quarter is 13.15, with the price to cash flow ratio at 65.63.
Edwards Lifesciences Corporation’s quick ratio for the period ended June 29 was 2.90, with the current ratio over the same period at 3.70 meaning that EW stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.12, while the total debt to equity was 0.12. In terms of profitability, the gross margin trailing 12 months is 75.50%. The trailing 12-month EBITDA margin is 32.63% while for the period ending June 29; Edwards Lifesciences Corporation’s operating margin was 33.20%. The firm’s gross profit as reported stood at $3.31 billion against revenue of $4.39 billion.
For the quarterly period ending June 29 this year, Edwards Lifesciences Corporation’s cash and short-term investments amounted to $248.4 million against total debt of $684.2 million. Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 32.78% to $1.38 billion, while revenue of $1.22 billion was 11.58% off the previous quarter. Analysts expected EW to announce $0.56 per share in earnings in its latest quarter, but it posted $0.64, representing a 14.30% surprise. EBITDA for the quarter stood at more than $577.9 million. EW stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 2.53 billion, with total debt at $684.2 million. Shareholders hold equity totaling $623.33 million
Let’s look briefly at Edwards Lifesciences Corporation (EW) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 11 October was 32.16% to suggest the stock is trending Neutral, with historical volatility in this time period at 32.59%.
The stock’s 5-day moving average is $109.28, reflecting a +1.99% or $2.12 change from its current price. EW is currently trading -9.10% above its 20-day SMA, +19.64% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -3.37% and +22.89% respectively.
Stochastic %K and %D was 23.01% and 24.44% and the average true range (ATR) pointed at 2.87. The RSI (14) points at 35.12%, while the 14-day stochastic is at 17.55% with the period’s ATR at 2.77. The stock’s 9-day MACD Oscillator is pointing at -0.83 and -3.74 on the 14-day charts.
In the most recent analyst report for Edwards Lifesciences Corporation (NYSE: EW), Wells Fargo reiterated its an Equal weight rating for the company but lifted their price target by $93 to $115. Analysts offering their rating for EW stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate EW as a “sell,”, while 11 advise that investors “Hold.” 1 analysts have rated the stock as underweight. 2 rates the stock as overweight while 13 have offered a “buy” rating.
What is EW’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $105.00 and a high of $135.00, with their median price target at $123.00. Looking at these predictions, the average price target given by analysts is for Edwards Lifesciences Corporation (EW) stock is $121.48.